Matrixyl
Palmitoyl pentapeptide-4
- Injection
- Oral
- Nasal spray
- Suppository
- Gel or cream
Gel or cream — applied to the skin, at parts-per-million.
Sold over the counter — no prescription needed
Matrixyl is a trademark, not a molecule. Sederma owns it, and underneath sits palmitoyl pentapeptide-4 — written pal-KTTKS by people who work with it. Five amino acids: lysine, threonine, threonine, lysine, serine. Attached to the front, a sixteen-carbon fatty acid.
The peptide half is the interesting part, because KTTKS was not designed. It is a fragment of human pro-collagen I — the protein your skin makes when it builds collagen. When tissue remodels itself, enzymes cut pro-collagen into pieces, and some of those pieces appear to carry signals of their own. That category has a name, matrikines, and it is real biology: damage generates fragments, fragments tell nearby cells to rebuild, the loop closes. The hypothesis behind this ingredient is that supplying the fragment from the outside reads to a fibroblast as evidence that collagen turnover is under way, and that the cell responds by making more.
In a dish it works: collagen I and III, fibronectin and hyaluronic acid all go up. What nobody has found is the receptor it works through.
That gap is the thing worth carrying away. Industry literature describes a TGF-β-mediated cascade with Smad signaling switching on the collagen and hyaluronan genes, and that map is plausible — it is also stated with more confidence than the published mechanistic work supports, because no specific cell-surface target for pal-KTTKS has been definitively identified in peer-reviewed work. The phenotype is reproducible. The middle of the pathway is inferred. And the large uplift percentages that appear in marketing decks come from the manufacturer’s own fibroblast cultures, which are real measurements on a different evidentiary tier from an independent human trial. For the study-by-study record, and for what separates Matrixyl from Matrixyl 3000 and Synthe’6, read the deep-dive on PeptideWellness.
Who it's for (or who should avoid)
What it's aimed at
As a cosmetic ingredient, the question is which cosmetic outcome it is aimed at:
- Fine lines and firmness — the endpoints the human studies actually measured, over months rather than weeks
- People who cannot tolerate retinoids — this is a low-irritation ingredient, and for a reactive barrier that is a real advantage over the actives with better data
- A layering step rather than a centerpiece — it does not compete with sunscreen or a retinoid for the same job, and it is not asking to
- Anyone who wants the ingredient rather than the trademark — pal-KTTKS appears in products at every price, and the INCI name on the back is what tells you it is there
What it is not aimed at: deep static wrinkles, laxity, volume loss, or pigmentation. Those are structural problems and a signaling fragment does not address them.
Who should avoid it
- Anyone expecting a needle-free equivalent of in-office work, which is how it is often sold and is not what the trials show
- People with reactive skin — patch-test, and remember a serum is a mixture, so the peptide may not be what stings
- Anyone pregnant or breastfeeding who wants a considered answer — topical cosmetic peptides are not systemically studied in pregnancy, and no evidence of harm is not evidence of safety; ask whoever manages your care
- Anyone comparing two products by the word on the front — Matrixyl, Matrixyl 3000 and Synthe’6 are three different things, and the copy treats them as one
Route, dose and course
Topically, at parts-per-million, over months. There is no prescription, no pharmacy and no clinician, and the protocol is as short as that.
What is actually worth attending to:
- Time horizon — collagen is a slow protein; the human work measures at months and there is no version of this that shows up in a fortnight
- Which Matrixyl — check the INCI name rather than the trademark, because the three products are not the same molecule
- Where it sits — a leave-on step on clean skin, comfortably alongside almost anything, which is part of the appeal
- What else is in the bottle — pal-KTTKS is rarely alone, and attributing a result to it specifically is harder than a label implies
The usual arc
Read this first. Collagen is a slow protein and this is a signaling nudge rather than a wound, so the honest unit here is months. The measurements in the literature are made on fibroblasts and on skin appearance, not on a biopsy of your face, and a good sunscreen is doing more for the same outcome over the same period.
The unit here is months, and the endpoint is appearance rather than a measured biological change. The arc below is the shape of that, including what the evidence says about stopping.
- MONTH 1Nothing structural yetAny improvement this early is hydration and the vehicle — a real cosmetic effect, and not the matrikine mechanism. Collagen synthesis does not turn around in four weeks, and no study claims it does.
- MONTH 2–3Where the human work measuresThe published studies report their endpoints across a few months of consistent use, on fine lines and firmness. Effect sizes are modest, the studies are small, and several were run by the ingredient's manufacturer.
- MONTH 6+Maintenance, not accumulationWhatever the effect is, it depends on continued signaling. There is no evidence of a structural change that persists once you stop, and no long-term independent trial that would settle the question either way.
Sold over the counter — no prescription needed
It is a cosmetic ingredient: it goes into serums you buy for yourself, so there is no prescriber to match you with and no provider price to quote.
What to check on the bottle
- The INCI name on the back, not the trademark on the front
- The concentration, on the brands that publish one
- What else is in the formula — the peptide is rarely the only active
Where the evidence is
Questions we get about Matrixyl
Does it build collagen?
In a dish, it reliably increases collagen I and III, fibronectin and hyaluronic acid output from human dermal fibroblasts. That result is reproducible and it is the honest core of the ingredient's case. What has not been established is a specific receptor — no cell-surface target for pal-KTTKS has been definitively identified in peer-reviewed work — so the story is "fragment goes in, collagen genes go up" with the middle steps inferred. And the large percentage uplifts that appear in marketing decks are manufacturer-run cell-culture measurements, which is a different tier of evidence from an independent randomised trial on human skin.
Is Matrixyl the same as Matrixyl 3000?
No, and this is the single most common confusion about it. Matrixyl, Matrixyl 3000 and Matrixyl Synthe'6 are three different Sederma products with different compositions, and consumer copy treats the names as interchangeable. If you are comparing two serums, compare the actual INCI names on the back, not the trademark on the front.
Do I need a prescription?
No. It is a cosmetic ingredient — no FDA approval is involved because none is required or available for it, and there is no prescriber, pharmacy or clinic in the picture. It appears in products from a few dollars upward, which is also why it is worth knowing what the evidence actually supports before paying for the expensive end.
See what licensed providers actually carry →How does it compare to retinol?
Not favorably, on evidence. Retinoids have decades of independent randomised human trials for photoaging and a mechanism established well past the inference stage. Matrixyl's case rests largely on fibroblast culture, much of it in-house, plus small human studies. The reasonable framing is that a peptide like this is a low-irritation addition to a routine, not a substitute for the actives that have the data — and that consistent sunscreen is doing more for the same endpoint than either.
Why does the fatty acid matter?
Delivery. Naked peptides do not cross the stratum corneum well, and the sixteen-carbon palmitoyl chain makes the molecule lipophilic enough to pass through lipid bilayers — in theory. It is the part of the design that turns an interesting fragment into something that might reach a fibroblast at all, and it is also a reminder of how much of this mechanism is reasoned rather than measured in skin.
We publish no medical reviewer by design. Every claim on this page traces to a source we hold on file, and the reviewed write-up with those citations lives on our hub. Read the full research on PeptideWellness ↗
Fuel your protocol with
the latest research + reviews
Independent updates on peptide therapy, breaking news from compounding pharmacies, and exclusive guides — straight to your inbox.
